Small amounts of alcohol deemed OK in early steatotic liver disease
Drinking a small amount of alcohol each day did not raise the mortality risk among people in the early stages of steatotic liver disease…
News
Livmarli’s long-term benefits in Alagille extend beyond itch: Study
Up to six years of treatment with Livmarli (maralixibat), which is approved for reducing itch, or pruritus, in Alagille syndrome, prolonged survival and…
Many viruses behind 2022 outbreak of hepatitis in children: Study
A global outbreak of severe hepatitis in children just after COVID-19 restrictions were lifted could have been caused by infections with multiple viruses at…
Seladelpar found to reduce disease activity, itch in PBC patients in trial
Daily treatment with seladelpar, CymaBay Therapeutics’ investigational oral candidate for people with primary biliary cholangitis (PBC), was shown to normalize liver biomarkers and…
Probiotics may help women with ICP, but risks not yet known
Women with intrahepatic cholestasis of pregnancy (ICP) show lesser diversity across their gut bacteria than do other pregnant women, a study reports. Its findings…
Survodutide lowers severe fatty liver disease severity in Phase 2 trial
Weekly injections under the skin of the experimental therapy survodutide significantly reduces the severity of metabolic-associated steatohepatitis (MASH), a severe form of fatty…
Gut microbiota may be noninvasive diagnostic tool in biliary atresia
The composition of microbes is altered in the intestines of infants with biliary atresia, a type of liver disease that affects the bile ducts,…
Many patients face barriers in accessing treatments for hepatitis C
While highly effective treatments for hepatitis C are available worldwide, many people — especially those living in poorer countries — are not able to access…
Patents covering CM-101, potential PSC therapy, given in Brazil, Israel
Chemomab Therapeutics has been awarded patents in Brazil and Israel covering CM-101, the company’s experimental therapy that’s currently being tested in a Phase…
Bortezomib helps girl avoid liver transplant rejection, return of PFIC2
Bortezomib, an anticancer medication, prevented a recurrence of progressive familial intrahepatic cholestasis type 2 (PFIC2) after a liver transplant by helping a young girl…
Recent Posts
- Biliary atresia patient spotlighted in 2025 ALF Liver Life Walk
- How I advocated for my brother before and after his PSC diagnosis
- Researchers uncover how hepatitis B virus can persist in liver cells
- CM-101 (nebokitug) set for primary sclerosing cholangitis Phase 3 trial
- Researchers develop tool to predict drug-induced cholestasis